Catalog No.
DHD72504
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
VH-VL-VH'-VL'
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
IL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P26951 & P07766
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, MGD-006, MGD006, RES234, S80880, CAS: 1664355-28-5
Clone ID
Flotetuzumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors., PMID:29206680
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity., PMID:29463552
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia., PMID:30280288
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia., PMID:32493790
Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia., PMID:32692611
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia., PMID:32929488
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML., PMID:33057635
A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy., PMID:33177106
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia., PMID:33630233
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building., PMID:34988912
Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia., PMID:35268423
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)., PMID:35368047
Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells., PMID:36563336
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm., PMID:36769040
[Management of AML in the elderly]., PMID:36870810
Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study., PMID:38629176
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia, PMID: 33630233
Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia, PMID: 32692611
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity, PMID: 29463552
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia, PMID: 30280288
A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy, PMID: 33177106
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors, PMID: 29206680
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia, PMID: 32493790
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML, PMID: 33057635
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia, PMID: 32929488
For research use only. Not for human or drug use.
